Prediction of 10-year distant recurrence (DR) using the Prosigna® (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR ) early breast c - Group C - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-03-18 04:49:43 Clinical medicine Cancer Medicine RTT Ribbon symbolism Breast cancer Adjuvant therapy Aromatase inhibitor Oncotype DX MammaPrint		Prediction of 10-year distant recurrence (DR) using the Prosigna® (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast c Add to Reading List Source URL: www.dbcg.dk Download Document from Source Website File Size: 1,76 MB Share Document on Facebook

	Programme d’accès au marché “PONDx”, Une nouvelle approche de collecte de données en vie réelle Utilisation du test Oncotype DX en pratique clinique courante S. Catala, Y. Coscas, N. Dohollou, A. Disset, C. Ta DocID: 1rZpG - View Document
	Prediction of 10-year distant recurrence (DR) using the Prosigna® (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast c DocID: 1qXDq - View Document
	DBCG DANISH BREAST CANCER COOPERATIVE GROUP Reference ListNo DocID: 1pxZ3 - View Document
	Radiotherapy Noncompliance and Clinical Outcomes in an Urban Academic Cancer Center Nitin Ohri, Bruce Rapkin, Chandan Guha, Shalom Kalnicki, Madhur Garg Albert Einstein College of Medicine and Montefiore Medical Center DocID: 1peIy - View Document
	ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. AdvocacyRockville Pike. Bethesda, MarylandTel: \| Fax: \| \| www.amp.org December 13, 2 DocID: 1mwpg - View Document